Pharmaceutical companies are exploring the potential of human drug mechanisms for use in animals, particularly in the pet market. This development is part of a broader trend of investing in new treatments, including those for diseases of aging, and may be influenced by efforts to reduce animal testing. The use of new approach methodologies, such as digital twins, is being considered as a possible alternative to traditional animal models, but its effectiveness is still being evaluated.